#NVCR hashtag - Bluesky

Japan’s health system to cover wearable lung cancer device Optune Lua National Health Insurance in Japan will reimburse Optune Lua for adults with advanced NSCLC, enabling access to TTFields therapy at qualified centers.

1 month ago

#NVCR Novocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer

www.stocktitan.net/news/NVCR/novocure-annou...

0 0 0 0

FDA approves Novocure’s Optune Pax for pancreatic cancer as 2025 sales climb FDA approval for Optune Pax, 8% revenue growth to $655.4M and 4,620 active patients underpin Novocure’s 2026 outlook of $675M–$705M and near breakeven.

1 month ago

#NVCR Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update

www.stocktitan.net/news/NVCR/novocure-repor...

0 0 0 0

Stock Master

@stockmaster70.bsky.social

1 month ago

📢 Stocks Trending NOW: #NBIS #FSLY #CSCO #CROX #SNDK #VKTX #SGN #ADYEN.AS #NVCR #BAX

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

3 months ago

Leading Indicators, Monday January 5, 2026 – Crystal Equity Research

Small-cap stocks in new uptrend according to average directional index, Mon Jan 5th - #MYO #TIGR #SKYT #PEPG #NVCR #MRAM #GHRS #CSWC #AZ #WEAV #EVTL #CRI #ACVA - More: crystalequityresearch.com/leading-indi... - #smallcap

0 0 0 0

Major Brain Cancer Treatment Breakthrough: Novocure's TTFields Now Covered in Spain's Health System TTFields therapy for newly diagnosed glioblastoma patients now available through Spanish National Health System. Treatment used by 35,000+ patients globally, marks 9th country for coverage.

7 months ago

#NVCR Novocure Announces Coverage of Tumor Treating Fields (TTFields) Therapy for Patients with Newly Diagnosed Glioblastoma in Spain

www.stocktitan.net/news/NVCR/novocure-annou...

0 0 0 0

Breakthrough Pancreatic Cancer Treatment: Novocure's TTFields Therapy Seeks FDA Approval After Success Novocure submits PMA application for TTFields therapy in locally advanced pancreatic cancer, following successful PANOVA-3 trial. FDA decision expected H2 2026.

7 months ago

#NVCR Novocure Submits Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer

www.stocktitan.net/news/NVCR/novocure-submi...

0 0 0 0

NovoCure Q2 Revenue Jumps 6 Percent | The Motley Fool

8 months ago

#NVCR #866a3033-3f44-4dfa-901f-84a2c9f610d6 #data-news

Origin | Interest | Match

0 0 0 0

Novocure: Steady Ahead of Key Milestones | The Motley Fool

8 months ago

#NVCR #f4c9dd3e-1c1a-485a-b999-7fbf03041bf9 #investing

Origin | Interest | Match

0 0 0 0

Novocure Reports Strong Q2 Earnings: Revenue Up 6%, Breakthrough Pancreatic Cancer Trial Selected for Best of ASCO Latest earnings show 4,331 active patients and promising PANOVA-3 trial results. Multiple FDA submissions planned for 2025. See full financial metrics and clinical milestones.

8 months ago

#NVCR Novocure Reports Second Quarter 2025 Financial Results

www.stocktitan.net/news/NVCR/novocure-repor...

0 0 0 0

Results From the Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting Novocure (NVCR) announced positive Phase 3 PANOVA-3 trial results for its Tumor Treating Fields (TTFields) therapy in pancreatic cancer, showing significant improvement in overall survival. When combined with gemcitabine and nab-paclitaxel, TTFields therapy demonstrated a median overall survival of 16.2 months versus 14.2 months in the control group (HR 0.82; p=0.039). The therapy showed notable improvements in one-year survival rates (68.1% vs 60.2%) and pain-free survival (15.2 vs 9.1 months). Quality of life metrics also improved significantly, with better outcomes in global health status, pain management, and digestive problems. The treatment was well-tolerated with only mild to moderate skin adverse events. Novocure plans to submit these results to the FDA in H2 2025 for premarket approval, with additional submissions planned for EU, Japan, and other markets.

10 months ago

#NVCR Results From the Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

www.stocktitan.net/news/NVCR/results-from-t...

0 0 0 0

Why NovoCure Stock Leaped 4% Higher Today | The Motley Fool

11 months ago

www.fool.com/investing/2025/04/24/why...

#NVCR #f76111ae-e6cc-4dad-ae51-113b8054d65b #investing

Result Details

0 0 0 0

Revolutionary Cancer Device Doubles Survival Time for Advanced Lung Cancer: New EU Approval Details New Optune Lua device shows groundbreaking 18.5-month survival in metastatic lung cancer with checkpoint inhibitors. Explore the transformative EU approval data.

11 months ago

#NVCR Novocure’s Optune Lua® Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer

www.stocktitan.net/news/NVCR/novocure-s-opt...

0 0 0 0

Original post on fool.com

11 months ago

www.fool.com/investing/2025/04/16/why...

#NVCR […]

[Original post on fool.com]

0 0 0 0

Can Novocure's Cancer Breakthroughs Outweigh Its $65.9M Quarterly Loss? Novocure achieved $605.2M in 2024 revenue with FDA approval for lung cancer treatment, despite $65.9M Q4 loss. Positive pancreatic cancer trial results expand pipeline.

1 year ago

#NVCR Novocure Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update

www.stocktitan.net/news/NVCR/novocure-repor...

0 0 0 0